Loteprednol: Difference between revisions
Citation bot (talk | contribs) m Alter: pages. Add: pmid, issue, title. You can use this bot yourself. Report bugs here. |
Anypodetos (talk | contribs) →top: Drugbox additions |
||
| Line 42: | Line 42: | ||
| ChEMBL_Ref = {{ebicite|changed|EBI}} |
| ChEMBL_Ref = {{ebicite|changed|EBI}} |
||
| ChEMBL = 1201389 |
| ChEMBL = 1201389 |
||
| ChEBI = 31784 |
|||
| synonyms = HGP 1 |
|||
<!-- Chemical data --> |
<!-- Chemical data --> |
||
| C=24 | H=31 | Cl=1 | O=7 |
| C=24 | H=31 | Cl=1 | O=7 |
||
| molecular_weight = 466.951 g/mol |
| molecular_weight = 466.951 g/mol |
||
| smiles = CCOC(=O)O[C@@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@H]3[C@H]2CCC4=CC(=O)C=C[C@]34C)O)C)C(=O)OCCl |
|||
| StdInChI=1S/C24H31ClO7/c1-4-30-21(29)32-24(20(28)31-13-25)10-8-17-16-6-5-14-11-15(26)7-9-22(14,2)19(16)18(27)12-23(17,24)3/h7,9,11,16-19,27H,4-6,8,10,12-13H2,1-3H3/t16-,17-,18-,19+,22-,23-,24-/m0/s1 |
|||
| StdInChIKey = DMKSVUSAATWOCU-HROMYWEYSA-N |
|||
}} |
}} |
||
Revision as of 07:13, 15 June 2016
 | |
| Clinical data | |
|---|---|
| Trade names | Lotemax |
| Other names | HGP 1 |
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| MedlinePlus | a606003 |
| Routes of administration | Eye drops |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.167.120 |
| Chemical and physical data | |
| Formula | C24H31ClO7 |
| Molar mass | 466.951 g/mol g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Loteprednol (as the ester loteprednol etabonate) is a corticosteroid used to treat inflammations of the eye. It is marketed by Bausch and Lomb as Lotemax.[1]
Medical uses
Ocular applications for this drug include the treatment of inflammation of the eye due to allergies, as well as chronic forms of keratitis (e.g. adenoviral and Thygeson's keratitis), vernal keratoconjunctivitis,[2] pingueculitis, and episcleritis.[citation needed]
Contraindications
As corticosteroids are immunosuppressive, loteprednol is contraindicated in patients with viral or fungal infections of the eye.[1][2]
Adverse effects
Common adverse effects include foreign body sensation in the eye, dry eye and epiphora (overflow of tears), chemosis (swelling of the conjunctiva), headache, and itching. Increased intraocular pressure, a side effect typical of corticosteroids, occurs in about 2% of patients.[1][2]
Interactions
The effect of drugs lowering intraocular pressure may be reduced. Loteprednol is not detectable in the bloodstream; so interactions with systemic drugs are highly unlikely.[1]
Physical and chemical properties
Chemical synthesis
![[icon]](/enwiki/wiki/File:Wiki_letter_w_cropped.svg){kind=small} | This section needs expansion. You can help by adding to it. |
See also
References
- ^ a b c d Haberfeld, H, ed. (2015). Austria-Codex (in German). Vienna: Österreichischer Apothekerverlag.
- ^ a b c Loteprednol Professional Drug Facts.
- ^ Druzgala, P.; Hochhaus, G.; Bodor, N. (1991). "Soft drugs—10. Blanching activity and receptor binding affinity of a new type of glucocorticoid: Loteprednol etabonate". J. Steroid Biochem. Mol. Biol. 38 (2): 149–54. doi:10.1016/0960-0760(91)90120-T. PMID 2004037.
{{cite journal}}: CS1 maint: multiple names: authors list (link)
Further reading
- Steward, R; et al. (November 1998). "Double-masked, placebo-controlled evaluation of loteprednol etabonate 0.5% for postoperative inflammation". J Cataract Surg. 24: 1480–1489.
- Pavesio, CE; Decory, HH (2008). "Treatment of ocular inflammatory conditions with loteprednol etabonate". Br J Ophthalmol. 92 (4): 455–459. doi:10.1136/bjo.2007.132621. PMID 18245274.